Integrative Treatment Explained with Chiropractic Care for Migraines

Discover effective treatment strategies through integrative chiropractic care to reduce migraine frequency and severity.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this comprehensive educational post, I take you on a clear, step-by-step journey through migraine—one of the most prevalent and disabling neurological disorders worldwide. Drawing on my multidisciplinary training and daily clinical experience, I explain how migraine differs from other headache types, why recognizing “red flag” symptoms is essential, and how the phases of a migraine attack unfold from prodrome to postdrome. I detail the latest pathophysiological insights centered on hypothalamic dysmodulation, trigeminovascular activation, serotonin signaling, and the pivotal role of Calcitonin Gene-Related Peptide (CGRP).

You will learn the mechanisms behind standard-of-care and novel therapies for acute and preventive treatment—triptans, ditans (5-HT1F agonists), gepants (CGRP receptor antagonists), monoclonal antibodies targeting the CGRP pathway, and onabotulinumtoxinA for chronic migraine. I also show where integrative chiropractic care fits—precise spinal adjustments, neuromuscular release, and postural rehabilitation—to reduce cervicogenic input into the trigeminal-cervical complex, normalize mechanoreceptor signaling, and raise the threshold for attacks.

This work is presented within our multidisciplinary care model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I collaborate closely with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933), an internist with over 40 years of experience. Together, we integrate chiropractic care, medical oversight, functional medicine, personal injury care, and rehabilitation to deliver personalized, evidence-based solutions for migraine. Throughout, I incorporate clinical observations from my practice and current literature, with APA-7 citations and linked references at the end.

Introducing Our Integrative Care Model and Why It Matters for Migraine

I am Dr. Alex Jimenez. As a Doctor of Chiropractic, Advanced Practice Registered Nurse, and Board-Certified Family Nurse Practitioner with certification in functional medicine and cranial-cervical techniques, my daily mission is to bridge disciplines to help patients with complex conditions like migraine. In El Paso, Texas, our clinic—Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic—has developed a multidisciplinary framework that aligns chiropractic neuromusculoskeletal expertise with high-level medical oversight and functional medicine inquiry.

• My roles:

• • DC (Doctor of Chiropractic): Neuromusculoskeletal diagnostics; cervical and thoracic spinal adjustments; soft tissue and myofascial care; postural rehabilitation.
  • APRN, FNP-BC (Advanced Practice Registered Nurse, Board-Certified Family Nurse Practitioner): Acute and preventive pharmacotherapy; care coordination; patient education and longitudinal management.
  • CFMP, IFMCP (Certified Functional Medicine Practitioner, Institute for Functional Medicine Certified Practitioner): Root-cause evaluation including nutrition, gut health, hormonal balance, micronutrient status, environmental exposures, and systems biology mapping.
  • ATN, CCST (Autonomic Training; Cranial-Cervical Subluxation Therapy): Focused assessment and gentle interventions for upper cervical neuromechanics and autonomic regulation.

• Medical direction and collaborative oversight:

• • Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine
  • NPI: 1164426749; Texas MD License: J2933
  • Over 40 years of experience in internal medicine
  • Provides comprehensive medical supervision—differential diagnosis, safety monitoring, cardiovascular risk evaluation, and co-management of pharmacologic strategies.

• Integrated services:

• • Chiropractic care (me): spinal alignment, neuromuscular release, proprioceptive normalization.
  • Medical oversight (Dr. Cardenas): diagnostics; medication selection; safety; monitoring; comorbidity management.
  • Functional medicine: nutrition; gut-brain axis; micronutrients; hormonal and circadian rhythm balance; trigger identification.
  • Personal injury care and rehabilitation: whiplash and biomechanical trauma protocols; graded exercise; neuromotor retraining; ergonomic reconditioning.

This team-based approach ensures we manage migraine as a multisystem condition, not “just a headache.” We coordinate care to address central nervous system sensitization, peripheral nociceptive drivers, vascular and neuroimmune factors, and lifestyle triggers. Patients benefit from synchronized interventions that reduce attack frequency and severity while improving function.

The Widespread Impact of Migraine: Understanding the Epidemiology

Migraine is common, disabling, and often under-recognized in primary care, where most sufferers receive treatment. A clear grasp of its prevalence shapes how we deploy resources and triage care safely.

• Key epidemiology:

• • Global prevalence exceeds one billion people (Goadsby et al., 2017).
  • Gender difference: approximately one in five women and one in sixteen men have migraine (Goadsby et al., 2017).
  • Pediatric impact: about one in eleven children experience migraine; pre-menarchal rates are similar in boys and girls, implying non-hormonal contributors early in life (Goadsby et al., 2017).
  • Household burden: one in four U.S. households includes a person with migraine.
  • Primary care: around 70% of migraine patients are managed in primary care settings—making accurate screening and safe early treatment essential (Lipton et al., 2003).

• Why this matters:

• • High prevalence demands efficient detection tools and swift differentiation from secondary headaches.
  • Socioeconomic burden (lost productivity, missed school/work, caregiver strain) necessitates preventive plans.
  • Primary care clinicians must know “red flags,” modern pharmacologic options, and integrative strategies to tailor care effectively.

Identifying Migraine Safely: “Red Flags” Before Primary Headache Diagnosis

My first obligation when a patient presents with headache is to exclude secondary causes that can be life-threatening. We use the SNOOP mnemonic to codify “red flag” features (Headache Classification Committee of the IHS, 2018):

• S – Systemic symptoms or Secondary risk factors:

• • Fever, myalgias, unexplained weight loss.
  • History of cancer or HIV; new-onset headache during pregnancy.

• N – Neurologic signs or symptoms:

• • Focal deficits (hemiparesis); new confusion; seizure.
  • Papilledema on fundoscopic exam (intracranial hypertension).

• O – Onset:

• • “Thunderclap” headache peaking within one minute suggests subarachnoid hemorrhage—medical emergency.
  • Migraine typically evolves over hours with waxing and waning intensity.

• O – Older age of onset:

• • New headache in individuals over 50 requires evaluation for giant cell arteritis (jaw claudication, scalp tenderness, systemic symptoms); prompt steroids prevent vision loss.

• P – Pattern change or Precipitating factors:

• • Marked change from prior migraine pattern; headaches precipitated by Valsalva (cough/sneeze/strain); strictly positional headache (upright worse, supine relief) suggests CSF leak; headaches associated with sexual activity warrant vascular evaluation.

Clinically, we escalate to neuroimaging or urgent referral when SNOOP features are present. This is where Dr. Cardenas’ oversight is crucial—ensuring timely exclusion of secondary causes and safe pathways to migraine-specific care.

Migraine Diagnostic Criteria: How I Confirm Primary Migraine

Once red flags are excluded, I apply ICHD-3 criteria for migraine without aura (Headache Classification Committee of the IHS, 2018):

• At least five attacks lasting 4–72 hours (untreated or unsuccessfully treated).
• Headache with at least two:

• • Unilateral location (can be bilateral in up to 40%).
  • Pulsating quality (throbbing/pounding).
  • Moderate to severe intensity (functionally disabling).
  • Aggravation by routine physical activity (walking stairs, bending).

• During headache, at least one:

• • Nausea and/or vomiting.
  • Photophobia and phonophobia.

Differentiation from tension-type headache (TTH) hinges on whether activity worsens pain. If walking upstairs exacerbates the headache, I think migraine first. TTH tends to be bilateral, pressing/tightening, mild-to-moderate, and not aggravated by routine activity (Headache Classification Committee of the IHS, 2018).

Fast Screening in Busy Clinics: The ID Migraine Screener

To streamline identification, I use the ID Migraine Screener (Lipton et al., 2003):

• Three questions (PIN):

• • P – Photophobia: “Does light bother you when you have a headache?”
  • I – Impairment: “In the last three months, has a headache limited your activities for a day or more?”
  • N – Nausea: “Are you nauseated when you have a headache?”

• Two “yes” responses carry approximately 93% positive predictive value for migraine (in the absence of red flags).

This quick tool integrates well into primary care and telehealth workflows and guides appropriate next steps.

The Migraine Journey: Prodrome, Aura, Headache, Postdrome

Migraine unfolds across distinct phases. Recognizing them adds opportunities to intervene early and helps patients contextualize symptoms (Dodick, 2018):

• Prodrome (hours to 1–2 days before pain):

• • Mood changes, cognitive fog, sensory sensitivity, fatigue, yawning, food cravings, neck stiffness.
  • Hypothalamic activation and limbic connectivity likely drive these features (Schulte & May, 2016).
  • Clinical tip: patients can take acute meds early, rest, hydrate, and avoid triggers to blunt attack severity.

• Aura (in about 30% of patients):

• • Transient, fully reversible neurological symptoms—most commonly visual (scintillating scotoma, zigzag lights, expanding peripheral bands), as well as sensory (paresthesia marching from fingers to face), and language (transient aphasia).
  • Differentiating from TIA: migraine aura tends to be positive (added phenomena) and gradual; TIA is often negative (loss of function) and abrupt.

• Headache phase (4–72 hours):

• • Moderate to severe throbbing pain; nausea/vomiting; photophobia/phonophobia; worsened by routine activity.
  • Cutaneous allodynia indicates central sensitization—non-painful stimuli now feel painful.

• Postdrome (24–48 hours):

• • Fatigue, fog, tenderness, mood changes—the “migraine hangover.”
  • Counseling helps patients pace recovery and avoid rebound triggers.

A single attack can disrupt three to five days. Our plans address all phases, not just the headache.

Pathophysiology: How Migraine Starts and Why It Hurts

Modern migraine science has shifted from purely vascular theories to neurobiological dysmodulation involving central and peripheral systems (Goadsby et al., 2017; Ashina et al., 2019).

• Central mechanisms: a hyperexcitable, genetically primed brain

• • Strong heritability: first-degree relatives commonly affected.
  • Hypothalamic dysmodulation: heightened pre-attack activation aligns with prodrome symptoms—sleep-wake disruption, appetite changes, mood flux (Schulte & May, 2016).
  • Limbic interplay: emotional circuits heighten sensitivity to stress triggers.

• Peripheral mechanisms: trigeminovascular activation and CGRP

• • Trigeminal nerve endings innervate dura mater and meningeal vessels.
  • Neurogenic inflammation: trigeminal activation releases CGRP, Substance P, neurokinin A—causing vasodilation and vascular permeability (“inflammatory soup”).
  • Pain signaling: sensitized nociceptors fire to trigeminal nucleus caudalis (TNC) and thalamus.
  • Central sensitization: repeated attacks “wind up” brainstem/thalamic neurons—leading to allodynia and chronicity.

• Serotonin (5-HT) in context:

• • 5-HT1B receptors: cranial vessel vasoconstriction counters CGRP-driven dilation.
  • 5-HT1D receptors: presynaptic brake on CGRP release.
  • Triptans leverage both properties—critical for aborting the cascade.

Understanding these steps clarifies why specific drugs work, where chiropractic modulation helps, and how functional medicine targets triggers.

Integrative Chiropractic Care: Where Structure Meets Neurobiology

As a chiropractor and functional clinician, I consistently see upper cervical and occipital dysfunction in migraine patients. This region intersects anatomically with the trigemino-cervical complex (TCC), where sensory input from trigeminal and C1–C3 roots converge. This convergence explains why neck issues can amplify head pain and why resolving cervical mechanoreception can calm central circuits (Watson & Drummond, 2014; Bryans et al., 2011).

• Clinical observations from my practice (see dralexjimenez.com and LinkedIn profile):

• • Forward head posture: chronic screen time overloads suboccipital muscles, compressing occipital nerves and sending aberrant signals into the TNC.
  • Upper cervical joint restriction (C1/C2): faulty mechanoreceptor input into the brainstem contributes to “noise,” lowering the attack threshold.
  • Myofascial trigger points: sternocleidomastoid, trapezius, suboccipital tightness refer pain to periorbital and temporal regions, mimicking or triggering migraine.

• My chiropractic approach:

• • Thorough structural and neurological exam; imaging when indicated.
  • Specific, low-force adjustments: restore alignment and motion without overloading tissues; aim to normalize mechanoreceptor feedback and reduce nociceptive bombardment.
  • Soft tissue and myofascial release: deactivate trigger points; reduce peripheral sensitization sources.
  • Postural rehabilitation: deep neck flexor activation; scapular stabilizer training; ergonomic coaching to break daily strain cycles.

• Why it fits:

• • Reduces peripheral drivers into the TCC.
  • Normalizes proprioceptive input to the brainstem.
  • Raises migraine threshold; synergizes with pharmacologic prevention.
  • Decreases reliance on acute meds; lowers medication overuse headache risk (Rizzoli & Loder, 2011).

All interventions are coordinated with Dr. Cardenas to ensure safety—especially with comorbidities and concurrent medications.

Acute Migraine Treatment: Stopping an Attack Early

Patients need a reliable toolkit tailored to attack severity and individual risks. I stratify care and advise early treatment at the first signs—often during prodrome—when central sensitization is not yet entrenched.

• Mild attacks:

• • NSAIDs (ibuprofen, naproxen) or acetaminophen—assess GI/renal risks, hypertension, bleeding risk.
  • Diclofenac potassium liquid-filled capsule offers rapid onset.

• Moderate to severe attacks:
  • Triptans (5-HT1B/1D agonists): vasoconstrict dilated vessels and block CGRP release (Goadsby et al., 2017).
    • Formulations: oral tablets, orally disintegrating tablets (ODTs), nasal sprays, subcutaneous injections.
    • Innovations:

• • • • Sumatriptan 3 mg auto-injector: lower dose for patients who need injection efficacy but experienced side effects at 6 mg.
      • Permeation-enhanced nasal sprays; breath-activated nasal powder to accelerate absorption.
      • Combination rizatriptan + meloxicam: dual mechanism—serotonergic plus anti-inflammatory synergy.

• • • Contraindications: CAD, peripheral vascular disease, uncontrolled hypertension, stroke/TIA, hemiplegic/basilar migraine—Dr. Cardenas conducts cardiovascular risk assessment.
  • Dihydroergotamine (DHE 45):

• • • Now available in an auto-injector—rapid relief without complex preparation.
    • Nasal spray option; also used for cluster headache rescue in appropriate settings.

• • Ditans (lasmiditan; 5-HT1F agonist):

• • • Neuronal inhibition in trigeminal pathways without vasoconstriction—safer for vascular comorbidities (Urits et al., 2020).
    • Side effects: dizziness, sedation; 8-hour driving restriction; Schedule V status.
    • Strategic use: severe evening attacks at home—sedation synergizes with sleep, a natural abortive.

• • Gepants (ubrogepant, rimegepant, zavegepant):
    • CGRP receptor antagonists; block postsynaptic CGRP signaling without vasoconstriction (Ailani et al., 2021; Dodick et al., 2019; Lipton et al., 2020).
    • Advantages: low risk for medication overuse headache; suitable for cardiovascular contraindications.
    • Considerations:

• • • • CYP3A4 metabolism—watch for inducers (e.g., topiramate) and inhibitors (e.g., verapamil); dose adjustments may be needed.
      • Post-marketing surveillance indicates rare hypertension and Raynaud’s phenomenon—monitor blood pressure and counsel patients on extremity color changes/numbness.

• Clinical pearls:

• • If a triptan underperforms: combine with an NSAID or a dopamine antagonist (metoclopramide, chlorpromazine, promethazine) to enhance efficacy and treat nausea.
  • If a triptan causes side effects: consider gentler triptans (naratriptan, eletriptan, almotriptan) or reduce dose (e.g., sumatriptan 3 mg).
  • Recurrence: use longer half-life triptans (naratriptan, frovatriptan) or add longer-acting NSAID at dosing—especially useful in menstrual migraine, which can last up to 72 hours.
  • Gastric stasis: when nausea/vomiting present, prefer non-oral routes (nasal or injection) for timely absorption.
  • Excessive acute use (≥10 days/month for triptans/ergots/opioids; ≥15 days/month for simple analgesics): diagnose or suspect medication overuse headache; pivot toward prevention.

Preventive Treatment: Reducing Frequency, Severity, and Duration

We start prevention when migraines occur frequently (often ≥4 days/month), cause significant disability, or when acute medication overuse emerges. Decisions are collaborative—centered on the patient’s goals and readiness.

• Traditional oral preventive classes:

• • Beta-blockers: propranolol, metoprolol, timolol.
  • Antidepressants: amitriptyline, venlafaxine.
  • Anticonvulsants: topiramate, divalproex sodium.
  • Angiotensin II receptor blocker: candesartan (now elevated with strong evidence).

• Why they work:

• • Beta-blockers modulate adrenergic tone and central excitability.
  • Tricyclics/SNRIs influence pain modulation pathways and sleep.
  • Anticonvulsants stabilize neuronal membranes and reduce hyperexcitability.

• CGRP-targeted preventives:
  • Monoclonal antibodies (erenumab—receptor blocker; fremanezumab, galcanezumab, eptinezumab—ligand binders):

• • • Monthly subcutaneous or quarterly dosing (fremanezumab quarterly option; eptinezumab IV every 3 months).
    • Long half-lives; cellular catabolism minimizes drug-drug interactions—valuable for polypharmacy and hepatic concerns (Dodick, 2018).
    • Efficacy: significant reductions in monthly migraine days; some patients reach ≥75% reduction (Dodick, 2018).
    • Side effects: injection site reactions; erenumab-associated constipation—avoid in IBS-C or those on constipating agents; eptinezumab may cause nasopharyngitis/dizziness/nausea in a small subset.

• • Oral gepants for prevention (rimegepant ODT; atogepant):

• • • Rimegepant: every other day for prevention and can be used acutely on off-days (studied up to 18 tabs/month).
    • Atogepant: daily dosing; approved for episodic and chronic migraine (60 mg dose for chronic).
    • Side effects: nausea, constipation, somnolence/fatigue (often mitigated with nighttime dosing); occasional appetite reduction and modest weight loss.

• Chronic migraine prevention:

• • OnabotulinumtoxinA (Botox): FDA-approved since 2010 based on PREEMPT trials—31 injections across seven muscle groups every 12 weeks (Dodick et al., 2010).
  • CGRP mAbs and atogepant 60 mg: effective for chronic pattern (≥15 headache days/month, with ≥8 migraine days).

• How onabotulinumtoxinA works:

• • Blocks presynaptic release by cleaving SNAP-25—prevents CGRP and Substance P release at targeted nerve endings (Dodick et al., 2010).
  • Reduces peripheral sensitization and muscle tension triggers; synergizes with chiropractic care focused on the same anatomical regions.

• Clinical selection pearls:

• • Migraine + hypertension: beta-blocker or candesartan.
  • Migraine + depression/anxiety: amitriptyline or venlafaxine.
  • Migraine + insomnia: sedating tricyclic at bedtime.
  • Migraine + obesity: topiramate may aid weight loss.
  • Women of childbearing potential: avoid valproate and topiramate—teratogenic risks.
  • If one preventive underperforms: switch classes, combine agents, or move to CGRP-targeted therapy.
  • AHS 2024 position statements support CGRP agents as first-line for eligible patients, but payer “step-care” may require advocacy with evidence (American Headache Society, 2019; American Headache Society, 2024 conceptual updates).

How We Integrate Chiropractic, Medical Oversight, and Functional Medicine in Practice

In our clinic, we do not silo care. We blend interventions to match each patient’s biology, biomechanics, and lifestyle.

• Foundation of care (my role):

• • Chiropractic adjustments: precise, low-force mobilizations to normalize upper cervical and thoracic mechanics; reduce aberrant afferent signaling into the TNC.
  • Myofascial release: suboccipital, SCM, trapezius; deactivation of trigger points; reduce peripheral sensitization.
  • Postural rehabilitation: deep neck flexors; scapular stabilizers; ergonomic reconditioning; breathing mechanics; sleep hygiene.
  • Functional medicine evaluation: magnesium, riboflavin (B2), CoQ10; investigate gut dysbiosis and barrier function; tailor anti-inflammatory dietary patterns; identify food sensitivities; assess circadian rhythm stability.

• Medical oversight (Dr. Cardenas):

• • Safety and diagnostics: exclusion of secondary causes; cardiovascular screening; imaging decisions.
  • Pharmacologic management: selection of acute and preventive agents; monitor efficacy and side effects; adjust for CYP3A4 interactions; counsel on FDA safety signals (hypertension, Raynaud’s).
  • Comorbidity control: blood pressure, metabolic issues, sleep disorders, mood concerns.

• Personal injury care and rehabilitation:

• • Whiplash and cervical strain protocols; graded motor control; vestibular and ocular motor integration when indicated; return-to-work planning; functional capacity building.

• Patient empowerment:

• • Education: migraine phases; early intervention; medication timing; trigger mapping.
  • Headache diary: track attacks, triggers, medications, recovery.
  • Shared decision-making: prevention readiness; understanding trade-offs among classes; access solutions with payers.

This synergy consistently reduces attack frequency and severity, improves medication responsiveness, and improves quality of life.

Deepening the Physiology: Why Each Therapy and Technique Is Used

• Triptans:

• • Rationale: presynaptic 5-HT1D agonism inhibits CGRP release; 5-HT1B agonism reduces vasodilation. Best when taken early before central sensitization peaks (Goadsby et al., 2017).

• Ditans (lasmiditan):

• • Rationale: targets trigeminal neuronal signaling via 5-HT1F without vasoconstriction—crucial in patients with vascular risks (Urits et al., 2020).
  • Use case: severe attacks where sedation is beneficial; avoiding vasoconstrictors.

• Gepants:

• • Rationale: postsynaptic CGRP receptor blockade interrupts the”lock-and-key” step of pain transmission; valuable when triptans are contraindicated or poorly tolerated.
  • Prevention role: daily or alternate-day dosing raises the threshold by continuously limiting CGRP signaling (Ailani et al., 2021).

• Monoclonal antibodies:

• • Rationale: ligand or receptor sequestration shuts down CGRP for extended periods; long half-lives stabilize the system; minimal drug-drug interactions via cellular catabolism; prime choice in patients with polypharmacy.

• OnabotulinumtoxinA:

• • Rationale: cleaves SNAP-25 to block vesicular release pre-synaptically; reduces both sensory neuropeptide release and muscle contraction triggers; targeted PREEMPT sites align with common migraine hotspots (Dodick et al., 2010).

• Chiropractic adjustments and soft tissue care:

• Rationale: normalize aberrant proprioceptive input; reduce neck-derived nociceptive drive into TNC; interrupt the cervicogenic contribution to trigeminovascular activation (Bryans et al., 2011; Watson & Drummond, 2014).
• Longitudinal effect: builds resilience by changing daily mechanical “load” on the system.

• Functional medicine strategies:

• Rationale: correct magnesium deficiency (supports neuromuscular stability and neurotransmitter regulation), riboflavin and CoQ10 (mitochondrial energy) improve brain bioenergetics; gut barrier repair reduces systemic inflammation; circadian optimization stabilizes hypothalamic rhythms.

Each element targets a node in the pathophysiological cascade—central hypersensitivity, peripheral neurogenic inflammation, autonomic dysregulation, and biomechanical triggers—while accounting for patient-specific constraints.

Practical Case Patterns and My Observations

• Case pattern: Menstrual migraine

• Strategy: frovatriptan or naratriptan for longer coverage; NSAID synergy; sleep protection; magnesium repletion; hormonal rhythm awareness.
• Chiropractic: gentle upper cervical support pre-menstrual window; myofascial release of suboccipitals and SCM.

• Case pattern: Whiplash-associated migraine escalation

• Strategy: intensive cervical rehabilitation; occipital nerve offloading; early mAb deployment; DHE auto-injector for severe flares.
• Functional medicine: anti-inflammatory nutrition; omega-3 support; sleep retraining.

• Case pattern: Cluster of near-daily headaches with MOH

• Strategy: withdrawal protocol; bridge therapy with long-acting NSAID or steroid when appropriate; initiate CGRP preventive; liberal chiropractic and soft tissue normalization; biofeedback for autonomic rebalancing.
• Education: reframe toolkits; strict day-counting for acute meds.

These patterns repeatedly validate the integrated model—when you address biomechanical and biochemical lanes together, patients recover faster and relapse less.

Building a Personalized “Migraine Toolkit” With Patients

I co-create a toolkit so patients know exactly what to do as soon as prodrome starts:

• Detection:

• Recognize prodrome cues: neck stiffness, yawning, mood shifts, cravings.
• Track aura features: visual zigzags, marching tingles, transient word-finding problems.

• Action:

• Hydrate, reduce stimuli, take acute medication early (appropriate class).
• Use non-oral routes if nausea is present.
• Apply musculoskeletal self-care: gentle suboccipital release, controlled breathing, posture reset.
• Notify care team when attack pattern changes or red flags emerge.

• Prevention:

• Adherence to preventive agents; give mAbs 3–6 months for full effect.
• Continue cervical rehabilitation and posture work.
• Nutrition and sleep consistency; stress modulation.

With this structure, patients feel in control and prevent escalation to severe disability.

Safety, Monitoring, and Advocacy

• Medication safety:

• Triptans: screen vascular risks; dosing education.
• Gepants: monitor for blood pressure changes and Raynaud’s; review CYP3A4 interactions.
• mAbs: counsel on constipation risk with erenumab; monitor injection sites; set realistic timelines.
• OnabotulinumtoxinA: follow PREEMPT mapping; ensure proper intervals.

• Imaging and referrals:

• Apply SNOOP consistently; escalate to neuroimaging when indicated; coordinate with neurology for complex cases.

• Payer advocacy:

• Document disability and prior trials.
• Reference AHS statements supporting first-line CGRP therapy where appropriate (American Headache Society, 2019; American Headache Society, 2024 conceptual updates).
• Utilize headache diaries to demonstrate need.

• Multidisciplinary continuity:

• Regular case conferences with Dr. Cardenas.
• Shared dashboards for medication adherence and side effects.
• Rehab milestones and ergonomic compliance tracking.

Safety is paramount. Our systems ensure that innovation is coupled with vigilance.

Conclusion: A Coherent, Comprehensive Path Forward

Migraine demands a cohesive plan that respects its biology and the person living with it. By combining precision pharmacology (triptans, ditans, gepants, mAbs, onabotulinumtoxinA) with targeted chiropractic care and functional medicine, we create a therapeutic web that addresses central sensitization, peripheral drivers, vascular-neuroimmune dynamics, and lifestyle rhythms.

At Injury Medical Clinic PA, under the medical direction of Dr. Maria Guadalupe Cardenas, MD, we deliver this integrated model every day. Our patients learn to predict their attacks, intervene early, prevent recurrence, and rebuild resilience. The science has never been stronger, the tools have never been more targeted, and the integrative approach has never been more necessary.

If you are living with migraine, this path is designed to help you reclaim your days, your work, your family time, and your joy. That is our mission, and it is achievable.

References

• Ailani, J., Lipton, R. B., & Goadsby, P. J. (2021). Calcitonin gene-related peptide (CGRP) and CGRP receptor antagonists in migraine. New England Journal of Medicine, 385(8), 718–728.
• American Headache Society. (2019). The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Neck Pain, 59(1), 1–18.
• Ashina, M., Hansen, J. M., Do, T. P., & Olesen, J. (2019). Migraine and the trigeminovascular system—40 years of progress. Cephalalgia, 39(13), 1617–1625.
• Bryans, R., Descarreaux, M., Duranleau, M., Marcoux, H., Potter, B., Ruegg, R., & White, E. (2011). Evidence-based guidelines for the chiropractic treatment of adults with headache. Journal of Manipulative and Physiological Therapeutics, 34(5), 274–289.
• Dodick, D. W. (2018). CGRP-targeted monoclonal antibodies for migraine prevention: A new era in headache treatment. The Lancet Neurology, 17(5), 391–393.
• Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H.-C., & Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache: The Journal of Head and Face Pain, 50(6), 921–936.
• Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017). Pathophysiology of migraine: A disorder of sensory processing. Physiological Reviews, 97(2), 553–622.
• Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1–211.
• Lipton, R. B., Dodick, D. W., Sadovsky, R., Kolodner, K., Endicott, J., Hettiarachchi, J., & Harrison, W. (2003). A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology, 61(3), 375–382.
• Lipton, R. B., Croop, R., Stock, E. G., Stock, D. A., Morris, B. A., Frost, M., Dubowchik, G. M., & Conway, C. M. (2020). Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. New England Journal of Medicine, 381(2), 142–149.
• Rizzoli, P., & Loder, E. W. (2011). Triptan-induced medication overuse headache. Current Opinion in Neurology, 24(3), 238–244.
• Schulte, L. H., & May, A. (2016). The migraine generator revisited: Continuous scanning reveals hypothalamus activation during a migraine attack. Annals of Neurology, 80(5), 797–801.
• Urits, I., Wesp, B., Cushman, D., Ilesh, J., Kendell, R., Amgalan, A., Berger, A. A., Kassem, H., & Viswanath, O. (2020). Lasmiditan for the acute treatment of migraine: A review of the literature. Pain and Therapy, 9(2), 579–594.
• Watson, D. H., & Drummond, P. D. (2014). Cervical referral of head pain in migraineurs: Effects of sternocleidomastoid and trapezius muscle trigger point injection on headache frequency and intensity. Cephalalgia, 34(12), 944–954.
• American Headache Society. (2024). The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain, 64(1), 7–10.
• S. Food and Drug Administration. (2024). Drug Safety Communication: FDA warns of onset or worsening of hypertension and Raynaud’s phenomenon with CGRP antagonists for migraine.

SEO Tags: migraine diagnosis, migraine treatment, CGRP antagonists, triptans, ditans, lasmiditan, ubrogepant, rimegepant, atogepant, erenumab, fremanezumab, galcanezumab, eptinezumab, onabotulinumtoxinA, PREEMPT protocol, trigeminovascular system, central sensitization, hypothalamus, ID Migraine, tension-type headache, SNOOP mnemonic, integrative chiropractic care, cervical spine, occipital nerves, suboccipital muscles, functional medicine, magnesium riboflavin CoQ10, El Paso Texas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, internal medicine oversight, personal injury rehabilitation, medication overuse headache, post-marketing safety hypertension Raynaud’s